Alder BioPharmaceuticals to Host Conference Call to Discuss Fourth Quarter and Full Year 2016 Financial and Operating Results...
February 16 2017 - 8:00AM
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage
biopharmaceutical company developing monoclonal antibody
therapeutics, today announced that it will report its fourth
quarter and full year 2016 financial and operating results after
the close of U.S. financial markets on Thursday, February 23,
2017. Alder management will host a conference call and live
audio webcast to discuss the results and provide a general business
update at 5:00 p.m. ET the same day.
The live call may be accessed by dialing (877) 430-4657 for
domestic callers or (484) 756-4339 for international callers, and
providing conference ID number 60771333. The webcast will be
broadcast live and may be accessed from the Events &
Presentations page in the Investors section of Alder’s website
at www.alderbio.com. A replay will be available following the
call for 30 days.
About Alder
BioPharmaceuticals
Alder BioPharmaceuticals, Inc., is a clinical-stage
biopharmaceutical company that discovers, develops and seeks to
commercialize genetically engineered therapeutic antibodies with
the potential to meaningfully transform current treatment
paradigms. Alder's lead pivotal-stage product candidate,
eptinezumab, is being evaluated for migraine prevention.
Eptinezumab is a monoclonal antibody that inhibits calcitonin
gene-related peptide (CGRP), a protein that is active in mediating
the initiation of migraine. Alder is additionally evaluating
ALD1910, a preclinical product candidate also in development as a
migraine prevention therapy. ALD1910 is a monoclonal antibody that
inhibits pituitary adenylate cyclase-activating polypeptide-38
(PACAP-38), another protein that is active in mediating the
initiation of migraine. Clazakizumab, Alder's third program, is a
monoclonal antibody candidate that inhibits interleukin-6 and is
licensed to Vitaeris, Inc. For more information, please visit
http://www.alderbio.com.
Media Contacts:
David Schull or Victoria Meissner
Russo Partners, LLC
(212) 845-4271
(646) 942-5627
david.schull@russopartnersllc.com
victoria.meissner@russopartnersllc.com
Investor Relations Contact:
David Walsey
Alder BioPharmaceuticals Inc.
(425) 408-8032
ir@alderbio.com
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From Apr 2023 to Apr 2024